Orient Pharma Co., Ltd. researches, develops, manufactures, and sells drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson's and Alzheimer's diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules. The company was founded in 2008 and is based in Taipei, Taiwan.
No analyst coverage available for this stock.